<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093949</url>
  </required_header>
  <id_info>
    <org_study_id>SUBSTRATE-HD</org_study_id>
    <nct_id>NCT02093949</nct_id>
  </id_info>
  <brief_title>Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation</brief_title>
  <acronym>SUBSTRATE-HD</acronym>
  <official_title>Substrate Ablation Guided by Automatic High Density Mapping for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate a new AF Substrate mapping method based on automatic high density CFAE detection
      with a multipolar catheter (Pentaray) and the &quot; SCI 30-40 &quot; setting of CARTO CFAE algorithm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is observational :

      This substrate ablation method is performed routinely in the centers involved in the study
      so, patients were not assigned by the investigators to undergo a specific procedure because
      of the study, in all cases patient would have beneficiate from this substrate mapping
      ablation method.

      We assessed procedural and follow up outcomes of this subatrate ablation group and compared
      them with an historical control group undergoing conventional ablation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure</measure>
    <time_frame>up to 240 min</time_frame>
    <description>percentage of patient in sinus rhythm or in atrial tachycardia at the end of the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of Patients With Sinus Rhythm Conversion During the Procedure</measure>
    <time_frame>180 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiofrequency Time (Min)</measure>
    <time_frame>up to 300 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Free From Atrial Fibrillation 18 Months Post Ablation</measure>
    <time_frame>18 Months post ablation</time_frame>
    <description>% of patients in sinus rhythm or in atrial tachycardia assessed by ECG and/ot 24h-Holter monitoring and clinical examination during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Major Adverse Events During and up to 18 Months After Procedure</measure>
    <time_frame>18 months post ablation</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Sustained AF Duration</measure>
    <time_frame>from first AF episode to baseline</time_frame>
    <description>duration of the longest AF epiodes in months before ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean LA Volume</measure>
    <time_frame>baseline</time_frame>
    <description>Left Atrial volume before ablation in ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous AF at the Beginning of the Procedure</measure>
    <time_frame>baseline</time_frame>
    <description>Spontaneous AF at the beginning of the procedure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">152</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Studied</arm_group_label>
    <description>Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routine substrate ablation without pulmonary vein Isolation</intervention_name>
    <arm_group_label>Studied</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routine conventional ablation with pulmonary vein Isolation</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient from 18 to 85, with AF* (paroxysmal, and persistent AF) and indication of AF
        ablation (including redos)*

        *In accordance with the recommendation of European Society of Cardiology (2010).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient from 18 to 85, with AF* (paroxysmal, and persistent AF) and indication of AF
             ablation (including redos)* *In accordance with the recommendation of European Society
             of Cardiology (2010).

        Exclusion Criteria:

          -  organized atrial activity (Atrial tachycardia or Flutter)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Seitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Joseph hospital Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste de Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <results_first_submitted>October 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2017</results_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital St. Joseph, Marseille, France</investigator_affiliation>
    <investigator_full_name>SEITZ JULIEN</investigator_full_name>
    <investigator_title>MD , Cardiologist Rythmologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Substrate Ablation</title>
          <description>Between September 2013 and July 2014, 105 patients with AF were prospectively enrolled at three centers performing substrate ablation (without pulmonary vein isolation) routinely</description>
        </group>
        <group group_id="P2">
          <title>Historical Control</title>
          <description>The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Substrate Ablation</title>
          <description>Study population (n=105) Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation.</description>
        </group>
        <group group_id="B2">
          <title>Historical Control</title>
          <description>Validation set (n=47) The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11"/>
                    <measurement group_id="B2" value="58" spread="11"/>
                    <measurement group_id="B3" value="61" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paroxysmal AF</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nonparoxysmal AF</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Structural heart disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure</title>
        <description>percentage of patient in sinus rhythm or in atrial tachycardia at the end of the procedure</description>
        <time_frame>up to 240 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure</title>
          <description>percentage of patient in sinus rhythm or in atrial tachycardia at the end of the procedure</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Patients With Sinus Rhythm Conversion During the Procedure</title>
        <time_frame>180 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Study population (n=105) Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Validation set (n=47) The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.</description>
          </group>
        </group_list>
        <measure>
          <title>% of Patients With Sinus Rhythm Conversion During the Procedure</title>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiofrequency Time (Min)</title>
        <time_frame>up to 300 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiofrequency Time (Min)</title>
          <units>min</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Free From Atrial Fibrillation 18 Months Post Ablation</title>
        <description>% of patients in sinus rhythm or in atrial tachycardia assessed by ECG and/ot 24h-Holter monitoring and clinical examination during follow-up.</description>
        <time_frame>18 Months post ablation</time_frame>
        <population>Group Substrate ablation long term follow-up n= 96/105: 9 patients (8.6%) did not complete the follow up; 1 patient died (myocardial infarction) and 8 were lost because of relocation.
Historical control long term follow-up group n=44/47: 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</population>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation Long Term Follow Up</title>
            <description>Out of the 105 patients included in the substrate ablation arm, only 96 were included in the long term follow-up group.
9 patients (8.6%) did not complete the follow up: 1 patient died 2 months before the end of follow-up (myocardial infarction) and 8 were lost to follow-up because of relocation.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control Long Term Follow-up</title>
            <description>Out of the 47 patients included in the validation set arm, only 42 finished the 18-mlonth follow-up. 2 patients were lost to follow-up
Population at the end of follow up : 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Free From Atrial Fibrillation 18 Months Post Ablation</title>
          <description>% of patients in sinus rhythm or in atrial tachycardia assessed by ECG and/ot 24h-Holter monitoring and clinical examination during follow-up.</description>
          <population>Group Substrate ablation long term follow-up n= 96/105: 9 patients (8.6%) did not complete the follow up; 1 patient died (myocardial infarction) and 8 were lost because of relocation.
Historical control long term follow-up group n=44/47: 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Major Adverse Events During and up to 18 Months After Procedure</title>
        <description>Adverse events</description>
        <time_frame>18 months post ablation</time_frame>
        <population>Group Substrate ablation long term follow-up n= 96/105: 9 patients (8.6%) did not complete the follow up; 1 patient died (myocardial infarction) and 8 were lost because of relocation.
Historical control long term follow-up group n=44/47: 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</population>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation Long Term Follow-up</title>
            <description>Out of the 105 patients included in the substrate ablation arm, only 96 were included in the long term follow-up group.
9 patients (8.6%) did not complete the follow up: 1 patient died 2 months before the end of follow-up (myocardial infarction) and 8 were lost to follow-up because of relocation.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control Long Term Follow-up</title>
            <description>Population at the end of follow up : 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Adverse Events During and up to 18 Months After Procedure</title>
          <description>Adverse events</description>
          <population>Group Substrate ablation long term follow-up n= 96/105: 9 patients (8.6%) did not complete the follow up; 1 patient died (myocardial infarction) and 8 were lost because of relocation.
Historical control long term follow-up group n=44/47: 3 patients dropped out during the blanking period (1 died of heart failure and 2 relocated)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Sustained AF Duration</title>
        <description>duration of the longest AF epiodes in months before ablation</description>
        <time_frame>from first AF episode to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Study population (n=105) Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Validation set (n=47) The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Sustained AF Duration</title>
          <description>duration of the longest AF epiodes in months before ablation</description>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean LA Volume</title>
        <description>Left Atrial volume before ablation in ml</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Study population (n=105) Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean LA Volume</title>
          <description>Left Atrial volume before ablation in ml</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spontaneous AF at the Beginning of the Procedure</title>
        <description>Spontaneous AF at the beginning of the procedure</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Substrate Ablation</title>
            <description>Study population (n=105) Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous AF at the Beginning of the Procedure</title>
          <description>Spontaneous AF at the beginning of the procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from ablation to 18 month follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Substrate Ablation</title>
          <description>Study population (n=105)</description>
        </group>
        <group group_id="E2">
          <title>Historical Control</title>
          <description>Validation set (n=47)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Redo Pericardial effusion</sub_title>
                <description>occuring few months after initial ablation during second ablation procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Julien Seitz</name_or_title>
      <organization>Saint joseph hospital</organization>
      <phone>+330491807044</phone>
      <email>jseitz@hopital-saint-joseph.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

